LEAC-102 / Taiwan Bio - LARVOL DELTA

A Botanical Drug Extracted From Antrodia cinnamomea: A First-in-human Phase I Study in Healthy Volunteers. (PubMed, J Am Nutr Assoc) - "The outcomes suggested that LEAC-102 was well tolerated and safe in healthy adults and exhibited potential immunomodulatory function. Supplemental data for this article is available online at https://doi.org/10.1080/07315724.2022.2032868 ."

Journal • P1 data • Addiction (Opioid and Alcohol) • Dermatology • Fatigue • Hepatology • Immune Modulation • Immunology • Inflammation • Oncology • Urticaria • PD-1

LEAC-102 for Advanced Colorectal Cancer (clinicaltrials.gov) - P1/2; N=30; Not yet recruiting; Sponsor: Taiwan Leader Biotech Corp.; Trial completion date: Feb 2022 ➔ Feb 2024; Trial primary completion date: Feb 2022 ➔ Feb 2024

Clinical • Combination therapy • Trial completion date • Trial primary completion date • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • CRP • MRI

The new plant drug LEAC-102, which is used to assist in the treatment of colorectal cancer, has completed a clinical trial of healthy subjects, verified human safety, and obtained the consent of the Food and Drug Administration (TFDA) of weifu [Google Translation] (Yahoo News) - "The company developed the new drug LEAC-102, with the top medical center team to carry out clinical trials, recently. The dose increment phase of the first phase of healthy subjects has been completed, the main objective of which is to determine the safety of LEAC-102 in the human body...LEAC-102 has been proven to be safe in all dosage groups and the subjects are well-to-do. will be carried out...The Phase I/IIa clinical trial is expected to combine the standard chemotherapy 5-Fluorouracil with LEAC-102"

New P1/2 trial • Non-US regulatory • Trial status • Colorectal Cancer • Gastrointestinal Cancer • Oncology